Prime Medicine, Inc. (NasdaqGM: PRME)
Health Care · Biotechnology · US
$3.61
-9.52% today · -36.1% 1Y
Prime Medicine, Inc. (NasdaqGM: PRME) operates in the Biotechnology industry within the Health Care sector. The company is valued at $642.23M and employs 146 people.
Over the last twelve months the share price has lost 36.1%, trading between 2.67 and 6.65.
Tweenvest scores Prime Medicine, Inc. across four factors: quality 35/100, value 51/100. Its strongest factor is value.
PRME price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $642.23M
- Revenue (TTM)
- $4.07M
- P/E
- —
- EPS
- -1.09
- Dividend yield
- —
- Beta (5Y)
- 2.38
- 52-week high
- $6.65
- 52-week low
- $2.67
- Avg volume (3M)
- —
- Shares outstanding
- 177.90M
- Employees
- 146
- Next earnings
- —
About Prime Medicine, Inc.
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.
- ISIN
- US74168J1016
- Founded
- 2019
- Listed since
- Oct 20, 2022
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Sunmax Biotechnology Co., Ltd.TPEX: 4728 | $674.51M | NT$396.00 | +0.38% |
| Faeth Therapeutics, Inc.NasdaqCM: FTH | $672.63M | $23.25 | -10.68% |
| Abbisko Cayman LimitedSEHK: 2256 | $665.94M | HK$7.89 | -9.83% |
| Beijing Bohui Innovation Biotechnology Group Co., Ltd.SZSE: 300318 | $646.39M | CN¥5.30 | +1.34% |
| Crescent Biopharma, Inc.NasdaqCM: CBIO | $638.16M | $14.46 | -3.02% |
| Medigen Vaccine Biologics CorporationTPEX: 6547 | $637.45M | NT$62.00 | +1.97% |
| CK Life Sciences Int'l., (Holdings) Inc.SEHK: 775 | $636.85M | HK$0.52 | -1.89% |
| Elixiron Immunotherapeutics (Cayman) LimitedTPEX: 7871 | $634.12M | NT$151.00 | -1.95% |
Figures last refreshed Oct 11, 2026.